THE TAPE
MGTX · Biotechnology · $839.4M

MeiraGTx Holdings plc Ordinary Shares

$8.74▼ −4.79%
Last close
Relative strength
18RS
of 99, against every stock▼ -12 on the month
Falling back
Unconfirmed
−24.3%
six months against Biotechnology
52-week range
−43.1%
from the high
$6.62$15.35
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
2 days
Nov 18 · confirmed
Growth REALProof PENDING
Quarter to Sep 30, revenue +1074% on a year ago
Why it is on no screen

MGTX is off the screens on 3 checks.

A base has formed18.8 weeks, from 8.44 to 15.35.
Long enough to count18.8 weeks against 3 needed.
Shallow enough45.0% deep against 35% allowed.
Close to its pivot-43.1% from the pivot; listed down to -20%.
Relative strengthRS 18 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$9.10
+4.1% · tested 4× · last 10 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

MeiraGTx Holdings plc Ordinary Shares is not on any of the screens right now. Its relative strength rating is 18, and it sits in Biotechnology.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-8.5%
Three months against its industry
-32.9%
Six months against its industry
-24.3%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
2
days
Earnings in 2 days
Nov 18, 2026
  1. Earningsconfirmedin 2d
    Quarterly earnings
    Nov 18, 2026
How it moves on earnings

On average 7.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$401.9M
+1074.1% year on year
Operating margin
44.8%
Net margin
19.5%
Free cash flow
$-3.0M
-0.4% of market cap
Price to sales
2.09×
Price to earnings
10.7×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 12
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$4.8M
-98.5% QoQ · +1074.1% YoY
Gross margin
—
Net income
−$51.2M
Loss
Free cash flow
−$26.3M
Burning · 7q runway

What the numbers say

  • Good: Revenue +1074.1% year over year, -98.5% on the quarter
  • Weak: Net loss $51M
  • Weak: Burning cash: operating cash flow -$25M, free cash flow -$26M, better than -$39M last quarter · 7 quarters of cash at this burn
  • Weak: Growth externally funded: capex $2M against operating cash flow -$25M; share count +19.7% in a year
  • Good: Net cash $185M · cash $185M
Revenue by quarter
Free cash flow
Net income
shares +19.7% in a year · net cash $184.7M

What is not obvious

  • Weak: Cash flow quality: operating cash flow -$25M included a $585K deferred-revenue inflow; -$25M without it. Customers paid ahead of delivery
  • Weak: Stock compensation $8M added back against negative operating cash flow

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $51M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Reported resultsFiling · 2026-11-13
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-13
below 20d & 50d on 1.8x volume at 8.79
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-13
-9.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-13
-9.2% on earnings 2026-11-12
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
GappedTape · 2026-11-10
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
+5.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-9.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-24
-5.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
MeiraGTx Announces Oral Presentation at ObesityWeek 2026GlobeNewswire Inc. · 1 day agoAlpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 6 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
4
$1,969,350 total

Sold: Forbes Alexandria, Giroux Richard, Naylor Stuart.

Not counted above: 2 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-08-18 Forbes Alexandria · PRESIDENT & CEO, Directorsell62,000$859,320
2026-07-21 Giroux Richard · CFO & COOsell56,000$700,560
2026-07-07 Naylor Stuart · CHIEF SCI OFCR, OPHTHALMOLOGYsell2,547$35,301
2026-07-07 Naylor Stuart · CHIEF SCI OFCR, OPHTHALMOLOGYsell25,112$374,169
2026-06-10 Harris Keith R. · Directoroption exercise75,000
2026-05-27 Giroux Richard · CFO & COOgift7,000

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy5
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
MeiraGTx Holdings plc Ordinary Shares (MGTX) — The Tape